Strength Training and Longevity: Why Muscle Is the Organ of Ageing

The 2023 hallmarks-of-ageing framework lists twelve, among them deregulated nutrient sensing, chronic inflammation and the loss of proteostasis. Reading that list as someone interested in muscle, three of them stand out, because each is separately implicated in the biology of sarcopenia — that is our framing, not the review's. Yet in public conversation, muscle is still treated as an aesthetic project — something you build in your twenties and reluctantly maintain later. The research tells a different story. Skeletal muscle is now understood as a secretory organ, releasing myokines that signal to fat, liver, bone and brain, and muscle strength turns out to be one of the more consistent predictors of mortality in large population studies.

This article reviews what the evidence actually shows about strength training and longevity, why muscle strength matters more than muscle mass, and what the GLP-1 weight-loss era means for anyone over forty. The evidence is STRONG for an association between muscle-strengthening activity and lower mortality — but no randomised trial has shown that lifting weights extends human lifespan, and that gap deserves to be stated plainly.

The mortality signal: what the large studies found

The most comprehensive evidence comes from a 2022 systematic review and meta-analysis in the British Journal of Sports Medicine. Momma and colleagues pooled data from multiple cohort studies and found that muscle-strengthening activities were associated with a 10–17% lower risk of all-cause mortality, cardiovascular disease, total cancer, and diabetes. The maximum risk reduction appeared at roughly 30–60 minutes per week, with a J-shaped dose–response curve — benefits plateaued and may have attenuated beyond about 130–140 minutes per week of resistance exercise.

A pooled analysis of 11 population cohorts from the Health Survey for England and the Scottish Health Survey reached a similar conclusion: adults who reported any strength-promoting exercise had significantly lower all-cause and cancer mortality than those who did none, independent of aerobic activity. The effect was present even after adjusting for age, sex, BMI, smoking, and chronic disease.

These are observational data. Fitter, stronger people differ from sedentary people in many ways, so the association does not prove that starting to lift weights causes a longer life. But the consistency, the dose–response pattern, and the biological plausibility (see below) are why ageing researchers take the signal seriously.

Strength predicts survival better than mass

One of the most important — and underappreciated — findings in ageing science is that muscle strength is a stronger predictor of mortality than muscle mass. In the Health, Aging and Body Composition (Health ABC) study, Newman and colleagues followed 2,292 adults aged 70–79. Both grip strength and quadriceps strength were strongly associated with mortality over follow-up, whereas muscle size — measured by CT and DXA — was not. Low muscle mass did not explain the association between low strength and death.

The same pattern appeared at a global scale. The Prospective Urban Rural Epidemiology (PURE) study measured grip strength in 139,691 adults across 17 countries. Each 5 kg reduction in grip strength was associated with a 16% higher risk of all-cause mortality (HR 1.16, 95% CI 1.13–1.20) and a 17% higher risk of cardiovascular death (HR 1.17, 95% CI 1.11–1.24). Grip strength was a stronger predictor of death than systolic blood pressure.

This is why the updated European Working Group on Sarcopenia (EWGSOP2) now defines sarcopenia primarily by low muscle strength, using detection of low muscle quantity or quality only to confirm the diagnosis. The clinical pivot is clear: what your muscles can do matters more than how large they are on a scan.

What sarcopenia costs

Sarcopenia — the progressive loss of skeletal muscle strength and function with age — is not a cosmetic inconvenience. A 2022 systematic review and meta-analysis in Gerontology pooled data from multiple studies and found that sarcopenia was associated with roughly double the risk of death (HR 2.00, 95% CI 1.71–2.34), independent of population, definition used, or follow-up period. Beyond mortality, the cost shows up in everyday function. A 2019 systematic review and meta-analysis pooled 36 studies covering 52,838 older adults and found that sarcopenic individuals had a higher risk of falls (prospective studies: OR 1.89, 95% CI 1.33–2.68) and of fractures (prospective studies: OR 1.71, 95% CI 1.44–2.03) than non-sarcopenic individuals. An earlier meta-analysis restricted to prospective studies using the European working-group definition found sarcopenia was also associated with functional decline (pooled OR 3.03, 95% CI 1.80–5.12), with a higher rate of falls, and with more hospitalisations.

Strength also declines faster than mass — a phenomenon sometimes called "dynapenia." The Health ABC study measured both in 1,880 older adults over three years. Annualised leg-strength decline ran at roughly 2.6–4.1% per year depending on sex and ethnicity, about three times the rate at which leg lean mass was lost (approximately 1% per year). More striking still, participants who gained lean mass over those three years did not maintain or gain strength. Because strength falls either way, the level you build and hold earlier matters for a simple arithmetic reason: it sets how much you can afford to lose before daily tasks — climbing stairs, rising from a chair, carrying shopping — become difficult.

The metabolic dividend of lifting

Muscle does more than move your skeleton. The most direct evidence that lifting changes metabolism — rather than simply burning calories during the session itself — comes from randomised trials of blood-sugar control.

A 2022 systematic review and meta-analysis of 20 randomised controlled trials (1,172 participants) found that resistance training reduced HbA1c by a weighted mean difference of −0.39 percentage points (95% CI −0.60 to −0.18, p<0.001) in adults with type 2 diabetes, with greater strength gains moderating greater HbA1c reductions.

Resistance training also appears to lower chronic low-grade inflammation. A meta-analysis of randomised controlled trials in adults over 50 found that resistance training significantly reduced C-reactive protein (CRP), with a smaller and less certain signal for interleukin-6 (IL-6). The relationship appears to run in both directions. In the Longitudinal Aging Study Amsterdam, 986 men and women with a mean age of 74.6 years had muscle strength and mass measured and then measured again after three years of follow-up. The authors defined loss of muscle strength as a fall in grip strength of more than 40%, and on that definition they report that high IL-6 (above 5 pg/mL) and high CRP (above 6.1 µg/mL) at baseline carried a two- to three-fold greater risk of meeting it. The same two markers showed no consistent association with sarcopenia defined by muscle mass — another instance of strength and mass behaving differently.

These metabolic and inflammatory effects may be part of the mechanism linking strength to longevity, though the full causal chain is not yet established in humans.

The GLP-1 era: why lean mass suddenly matters more

The rise of GLP-1 receptor agonists has sharpened the conversation about muscle. These medicines produce substantial weight loss, and a 2024 systematic review of six trials covering 1,541 adults with overweight or obesity found that the weight lost was mostly fat. But the lean-mass share of the total varied enormously between studies — from close to zero up to around 40% — and the review notes that noteworthy decreases in lean mass were particularly evident in the larger trials. The same review adds that lean mass as a proportion of total body mass rose, which its authors read as a favourable overall outcome.

The honest summary is that the range is wide, the reasons for that variation are not settled, and the same percentage means more in absolute terms for someone who started with less lean tissue to begin with.

None of that is an argument against these medicines. They are prescription treatments, and whether one is appropriate is a matter for a patient and their doctor. Two large cardiovascular outcome trials in this drug class — one in adults with type 2 diabetes, one in adults with overweight or obesity and established cardiovascular disease but without diabetes — each reported a reduction in major adverse cardiovascular events in the population studied.

The point here is narrower, and it is a gap rather than a finding. Trials that combine a GLP-1 drug with exercise do exist: in a one-year randomised trial in adults with obesity, liraglutide combined with a moderate-to-vigorous exercise programme cut body-fat percentage by 3.9 percentage points, against 1.7 points for exercise alone and 1.9 points for liraglutide alone. But that programme was general endurance-led exercise rather than a structured resistance-training block, and we are not aware of a randomised trial testing whether adding progressive resistance training to semaglutide-class treatment protects lean mass or changes clinical outcomes. What is established is that resistance training builds and maintains strength, and that strength is what the mortality data track. Those two facts do not amount to proof, but they are why muscle is worth raising with your clinician if you are on, or considering, this class of drug.

What the evidence does not yet show

It would be dishonest not to state the gap. No randomised controlled trial has demonstrated that a resistance-training programme extends human lifespan. The large mortality associations cited above are all observational — prospective cohorts, pooled analyses, meta-analyses of cohorts — and carry the usual caveats about residual confounding. People who lift weights may differ in motivation, socioeconomic status, diet, and health consciousness in ways that statistical adjustment cannot fully capture.

What the evidence does show, at the level of STRONG observational data plus mechanistic support from RCTs, is that muscle-strengthening activity is consistently associated with lower mortality, that the association is dose-dependent, and that randomised trials show resistance training improves intermediate markers — HbA1c and CRP among them — that are themselves linked to chronic disease. That is a compelling — if incomplete — case.

How Omniwo helps you measure this

Omniwo cannot grip-test you, and it does not yet offer body-composition analysis — that sensing modality is on our roadmap, not purchasable today. What Omniwo does track is the metabolic dividend of strength training: the downstream signals that change when you lift consistently.

The Advanced Wellness Check includes HbA1c, a three-month average of blood glucose regulation that resistance training has been shown to lower in randomised trials. Because HbA1c reflects roughly the preceding three months, it is a marker worth re-testing after a training block rather than after a single week. It also includes a lipid panel and inflammatory markers, so you can see whether a training block is moving markers associated with cardiometabolic health in research. Watching those numbers move is not the same as changing your risk: the panel measures, it does not predict or prevent.

If you use WHOOP, it tracks strain and recovery, so you can see training load alongside your blood work. Strava and Apple Health log activity volume. Taken together, the picture is: train → re-test in 10–12 weeks → see the metabolic response in your own data, not the population average.

The honest framing: Omniwo measures what lifting does to your blood chemistry, not how strong you are. Grip strength, one-rep max, and lean mass are measured in the gym or the clinic, not from a blood sample. What a retestable panel gives you is the ability to see whether your training is producing the metabolic and inflammatory shifts the research associates with lower risk — and to adjust if it is not.

Omniwo's tests and content are for wellness and educational insight. They are not a medical device, do not diagnose, treat, cure or prevent any disease, and do not replace advice from a qualified healthcare professional.

Sources

1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023;186(2):243–278. doi:10.1016/j.cell.2022.11.001 (PMID: 36599349)
2. Momma H, Kawakami R, Honda T, Sawada SS. Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies. British Journal of Sports Medicine. 2022;56(13):755–763. doi:10.1136/bjsports-2021-105061 (PMID: 35228201)
3. Stamatakis E, Lee I-M, Bennie J, Freeston J, Hamer M, O'Donovan G, Ding D, Bauman A, Mavros Y. Does strength-promoting exercise confer unique health benefits? A pooled analysis of data on 11 population cohorts with all-cause, cancer, and cardiovascular mortality endpoints. American Journal of Epidemiology. 2018;187(5):1102–1112. doi:10.1093/aje/kwx345 (PMID: 29099919)
4. Newman AB, Kupelian V, Visser M, Simonsick EM, Goodpaster BH, Kritchevsky SB, Tylavsky FA, Rubin SM, Harris TB. Strength, but not muscle mass, is associated with mortality in the Health, Aging and Body Composition Study cohort. The Journals of Gerontology: Series A. 2006;61(1):72–77. doi:10.1093/gerona/61.1.72 (PMID: 16456196)
5. Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. The Lancet. 2015;386(9990):266–273. doi:10.1016/S0140-6736(14)62000-6 (PMID: 25982160)
6. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). Age and Ageing. 2019;48(1):16–31. doi:10.1093/ageing/afy169 (PMID: 30312372)
7. Xu J, Wan CS, Ktoris K, Reijnierse EM, Maier AB. Sarcopenia is associated with mortality in adults: a systematic review and meta-analysis. Gerontology. 2022;68(4):361–376. doi:10.1159/000517099 (PMID: 34315158)
8. Jansson AK, Chan LX, Lubans DR, et al. Effect of resistance training on HbA1c in adults with type 2 diabetes mellitus and the moderating effect of changes in muscular strength: a systematic review and meta-analysis. BMJ Open Diabetes Research & Care. 2022;10(2):e002595. doi:10.1136/bmjdrc-2021-002595 (PMID: 35273011)
9. Sardeli AV, Tomeleri CM, Cyrino ES, Fernhall B, Cavaglieri CR, Chacon-Mikahil MPT. Effect of resistance training on inflammatory markers of older adults: a meta-analysis. Experimental Gerontology. 2018;111:188–196. doi:10.1016/j.exger.2018.07.021 (PMID: 30071283)
10. Goodpaster BH, Park SW, Harris TB, Kritchevsky SB, Nevitt M, Schwartz AV, Simonsick EM, Tylavsky FA, Visser M, Newman AB. The loss of skeletal muscle strength, mass, and quality in older adults: the Health, Aging and Body Composition Study. The Journals of Gerontology: Series A. 2006;61(10):1059–1064. doi:10.1093/gerona/61.10.1059 (PMID: 17077199)
11. Schaap LA, Pluijm SMF, Deeg DJH, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. American Journal of Medicine. 2006;119(6):526.e9–526.e17. doi:10.1016/j.amjmed.2005.10.049 (PMID: 16750969)
12. Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opinion on Pharmacotherapy. 2024;25(5):611–619. doi:10.1080/14656566.2024.2343092 (PMID: 38629387)
13. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141 (PMID: 27633186)
14. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389(24):2221–2232. doi:10.1056/NEJMoa2307563 (PMID: 37952131)
15. Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nature Reviews Endocrinology. 2012;8(8):457–465. doi:10.1038/nrendo.2012.49 (PMID: 22473333)
16. Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine. 2021;384(18):1719–1730. doi:10.1056/NEJMoa2028198 (PMID: 33951361)
17. Yeung SSY, Reijnierse EM, Pham VK, et al. Sarcopenia and its association with falls and fractures in older adults: a systematic review and meta-analysis. Journal of Cachexia, Sarcopenia and Muscle. 2019;10(3):485–500. doi:10.1002/jcsm.12411 (PMID: 30993881)
18. Beaudart C, Zaaria M, Pasleau F, Reginster JY, Bruyère O. Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS One. 2017;12(1):e0169548. doi:10.1371/journal.pone.0169548 (PMID: 28095426)

This article is educational and not medical advice. See our medical disclaimer.